drugset / Trial / NCT06496750

Ketamine for Methamphetamine Use Disorder

NCT06496750

Phase 2 Recruiting 120 enrolled University of Texas Southwestern Medical Center
RandomizedParallel-groupTriple-blindTreatment

Summary

This study aims to determine whether treatment response with IV ketamine is superior to treatment response with IV midazolam in adults with moderate to severe MUD. The study design is a 12-week randomized, double-blind, controlled trial comparing intravenous (IV) ketamine against IV midazolam, delivered over six weeks in 120 adults with moderate to severe methamphetamine use disorder (MUD).

Timeline

Start
2024-09-11
Primary completion
2026-08-18
Completion
2026-10-15

Drugs

EvaluationDrugModalityDoseRoute
Subject Ketamine Small molecule 0.5 mg/kg Intravenous
Comparator Midazolam Small molecule 0.02 mg/kg Intravenous

Indications